What's better than a good thing? More of a good thing. Income investors can find plenty of "good things" in the market these ...

SAN FRANCISCO -- More adults with moderate-to-severe Crohn's disease (CD) reached clinical remission after 6 months on ...

Invest in essential sectors like consumer staples and energy to beat inflation. See why these stocks offer reliable dividends ...

Global oncology portfolio sales were $1.7 billion, up 12%. Imbruvica sales were $848 million, down 6%. Venclexta sales were $655 million, up 11%. Elahere revenues were $148 million.

Look, people on Wall Street, you better start taking the President of the United States more seriously or else you ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

ABBV stock, with 24% returns since the beginning of 2024, has marginally underperformed the S&P 500 index, up 27%. An ...

Tariffs and price inflation for specialty medications will increase costs, according to research from Vizient.

Raymond James analyst Gary Nachman raised the firm’s price target on AbbVie (ABBV) to $220 from $218 and keeps an Outperform rating on the ...

Citi raised the firm’s price target on AbbVie (ABBV) to $215 from $205 and keeps a Buy rating on the shares. AbbVie repeated its usual beat in ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

AbbVie shares rose 5.5% Friday, after the company hiked its sales forecasts for two key drugs. The company reported fourth-quarter revenue and earnings above Wall Street's estimates, and forecast that ...